MRNS Investors Have Opportunity to Lead Schal Law Firm’s Marinus Pharmaceuticals, Inc. Securities Lawsuit

LOS ANGELES, July 3, 2024 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Marinus Pharmaceuticals, Inc. (“Marinus” or the “Company”) (NASDAQ trading under the symbol MRNS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10(b) and 10(b) of the Securities Exchange Act of 1934. 10b-5 issued thereon by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities in the period from March 17, 2021 AND May 7, 2024inclusive (hereinafter referred to as the “Class Period”), we encourage you to contact the company before August 5, 2024.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact us Brian Schall Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335 to discuss your rights free of charge. You can also contact us through the firm’s website at www.schallfirm.com or by email at (email protected).

The class in this case has not yet been certified, and until it is certified, you will not be represented by an attorney. If you decide not to take any action, you may remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Marinus underestimated the risk of failure of its RAISE study. The Company failed to inform investors that the potential consequence of failure to meet the early stop criteria in the RAISE study would be the stoppage of the separate Phase 3 RAISE II study. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Marinus, investors suffered harm.

Join the cause and recover your losses.

The Schall Law Firm represents investors throughout the world and specializes in securities class action lawsuits and shareholder rights disputes.

This press release may be considered attorney advertising in some jurisdictions under applicable law and rules of ethics.

CONTACT:
Schall Law Firm
Brian Schall, Attorney at Law,
www.schallfirm.com
Office: 310-301-3335
(email protected)

SOURCE Schall Law Firm